Strontium: Supply-and-demand success for the DOE’s Isotope Program

May 2, 2024, 3:15PMNuclear News
ORNL’s High Flux Isotope Reactor, where Sr-89 and other radioisotopes are produced, photographed during a 2015 refueling. (Photo: ORNL)

The Department of Energy’s Isotope Program (DOE IP) announced last week that it would end its “active standby” capability for strontium-82 production about two decades after beginning production of the isotope for cardiac diagnostic imaging. The DOE IP is celebrating commercialization of the Sr-82 supply chain as “a success story for both industry and the DOE IP.” Now that the Sr-82 market is commercially viable, the DOE IP and its National Isotope Development Center can “reassign those dedicated radioisotope production capacities to other mission needs”—including Sr-89.

The road to wellness: The task of getting lifesaving medical isotopes to patients

February 2, 2024, 3:01PMNuclear NewsTim Gregoire
A vial of Ac-225 produced by Niowave stands next to its lead shipping pig. (Photo: Niowave)

According to the Council on Radionuclides and Radiopharmaceuticals, more than 82,000 nuclear imaging procedures using nuclear medicine are performed throughout the world every day. To administer these vital medical procedures, radiopharmaceutical companies and hospitals rely on a handful of producers of medical radioisotopes.

Serva Energy teams with research reactor to produce cancer-fighting Ac-225

June 27, 2023, 7:00AMNuclear News

Serva Energy has developed a research reactor–based method of actinium-225 production, the company announced on June 22, saying it “marks the first time a commercial entity has employed a conventional nuclear reactor to produce the lifesaving isotope—allowing for dozens of existing research reactors around the world to collaborate with Serva on increasing production of Actinium-225 without huge capital investments or delays for construction.”

Webinar: International isotope supply chain needs coordination, not complacency

June 1, 2022, 9:30AMNuclear News

Accelerators and other new facilities are producing an increasing share of the radioisotopes that were once sourced solely from a handful of research reactors around the globe; demand for alpha-emitters is increasing; and the need for an ensured supply of both radioactive and stable isotopes is now heightened as many countries seek an alternative to Russian isotopes. Those are just a few of the key points that emerged from a recent webinar, “Demand and Supply of Isotopes Around the World: From Diverse Perspectives,” organized by the World Council of Isotopes, along with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation and the University of Saskatchewan, the hosts of the upcoming 11th International Conference on Isotopes (11ICI).

Protein shows potential to accelerate cancer therapy research and application

October 25, 2021, 3:05PMNuclear News
LLNL and Penn State researchers developed a new approach to study and purify medical isotopes, including actinium. (Image: Thomas Reason/LLNL)

Scientists at Lawrence Livermore National Laboratory and Pennsylvania State University have demonstrated that a natural protein found bonded to rare earth elements can be recovered and used as a tool to purify and effectively manage radioactive metals that show promise for cancer therapy and the detection of illicit nuclear activities.

SHINE plans new isotope production facility in the Netherlands

May 24, 2021, 7:00AMNuclear News
A rendering of the SHINE medical isotope production facility planned for construction in Veendam, the Netherlands. (Image: Shine)

SHINE Medical Technologies plans to locate its European medical isotope production facility in the Netherlands after a yearlong search and a review of more than 50 proposals from sites across Europe. The company announced on May 20 that construction at the site should begin in 2023 with commercial production starting in late 2025.